HC Wainwright Has Positive Outlook for FULC FY2028 Earnings

Fulcrum Therapeutics, Inc. (NASDAQ:FULC) – Equities research analysts at HC Wainwright lifted their FY2028 earnings per share (EPS) estimates for shares of Fulcrum Therapeutics in a research report issued on Monday, November 24th. HC Wainwright analyst A. Fein now expects that the company will earn $0.45 per share for the year, up from their prior estimate of ($1.01). HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for Fulcrum Therapeutics’ current full-year earnings is ($0.16) per share. HC Wainwright also issued estimates for Fulcrum Therapeutics’ FY2029 earnings at $1.20 EPS.

Several other equities research analysts have also recently weighed in on the stock. Wall Street Zen cut shares of Fulcrum Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 1st. Leerink Partners set a $20.00 price target on Fulcrum Therapeutics and gave the company an “outperform” rating in a report on Tuesday, October 21st. Truist Financial set a $14.00 price objective on Fulcrum Therapeutics in a research note on Monday. Piper Sandler reaffirmed an “overweight” rating and set a $16.00 price objective (up previously from $12.50) on shares of Fulcrum Therapeutics in a research report on Thursday, October 30th. Finally, Royal Bank Of Canada boosted their target price on shares of Fulcrum Therapeutics from $5.00 to $7.00 and gave the stock a “sector perform” rating in a report on Thursday, October 30th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Fulcrum Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $14.17.

Fulcrum Therapeutics Price Performance

Shares of Fulcrum Therapeutics stock opened at $11.54 on Wednesday. The stock has a market cap of $624.54 million, a price-to-earnings ratio of -9.78 and a beta of 3.02. The firm’s 50-day moving average is $9.04 and its two-hundred day moving average is $7.68. Fulcrum Therapeutics has a 1 year low of $2.32 and a 1 year high of $12.19.

Fulcrum Therapeutics (NASDAQ:FULC) last released its quarterly earnings data on Wednesday, October 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.02).

Insiders Place Their Bets

In related news, Director Robert J. Gould sold 15,000 shares of the company’s stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $11.03, for a total transaction of $165,450.00. Following the transaction, the director directly owned 484,864 shares of the company’s stock, valued at $5,348,049.92. This represents a 3.00% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 7.00% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of large investors have recently modified their holdings of the business. PharVision Advisers LLC purchased a new stake in shares of Fulcrum Therapeutics during the third quarter worth about $220,000. Quarry LP purchased a new position in shares of Fulcrum Therapeutics in the 3rd quarter valued at approximately $35,000. Nantahala Capital Management LLC boosted its stake in Fulcrum Therapeutics by 8.9% in the 3rd quarter. Nantahala Capital Management LLC now owns 4,670,784 shares of the company’s stock worth $42,971,000 after purchasing an additional 382,485 shares in the last quarter. Millennium Management LLC grew its position in Fulcrum Therapeutics by 42.7% during the 3rd quarter. Millennium Management LLC now owns 150,867 shares of the company’s stock worth $1,388,000 after purchasing an additional 45,174 shares during the last quarter. Finally, Brevan Howard Capital Management LP purchased a new stake in Fulcrum Therapeutics during the 3rd quarter worth approximately $141,000. Hedge funds and other institutional investors own 89.83% of the company’s stock.

About Fulcrum Therapeutics

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.